Statin Adherence Associated With Increased Type 2 Diabetes Risk | NDEI

Click here for the NDEI.org Slide Library.
Click here to return to NDEI.org.

  • Continuous statin use was associated with increased risk of new-onset type 2 diabetes in a cohort study investigating the relationship between increasing levels of statin adherence and type 2 diabetes.
  • A significant trend toward increased risk of new-onset diabetes was seen with increasing statin adherence. The benefits of statins in reducing cardiovascular events overwhelm the diabetes risk.
    • Excess risk of new-onset diabetes among subjects with more continuous statin use vs subjects using statins for shorter time
    • Statistical evidence that effect of statins on diabetes risk differed based on potency
  • HR (95% CI) for diabetes by proportion of days covered (PDC):*†
    • Very low (PDC <25%): 1.00 (reference)
    • Low (PDC 25-49%): 1.12 (1.06-1.18)
    • Intermediate (PDC 50-74%): 1.21 (1.14-1.27)
    • High (PDC ≥75%): 1.32 (1.26-1.39)

*PDC=cumulative number of days medication was available divided by days of follow-up
Estimates for all statins; adjusted for age, sex, first-line statin therapy, concomitant use of other drugs, cardiovascular disease history, and comorbidities

This cohort study investigated the relationship between increasing levels of statin adherence and type 2 diabetes. Subjects were from the database of National Health Service in Italy and had ≥1 new statin prescription and no prior diabetes (N=115,709). Adherence was assessed by proportion of days covered (PDC): the cumulative number of days medication was available divided by days of follow-up. Adherence was categorized as very low (PDC <25%), low (PDC 25-49%), intermediate (PDC 50-74%), and high (PDC ≥75%). PDC categories were also considered based on statin potency: rosuvastatin ≥10 mg, atorvastatin ≥20 mg, and simvastatin ≥40 mg considered higher potency; all other statins classified as lower potency. The study outcomes were initiation of antihyperglycemic therapy or hospitalization for type 2 diabetes.

Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014;37(8):2225-2232.

Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States.

August 2014

This slide was created by KnowledgePoint360 Group, LLC, and was not associated with funding via an educational grant or a promotional/commercial interest.